Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Finckh, Axel; Mc Carthy, Geraldine M; Madigan, Anne; Van Linthoudt, Daniel; Weber, Marcel; Neto, David; Rappoport, Georges; Blumhardt, Sandra; Kyburz, Diego; Guerne, Pierre-André

doi:10.1186/s13075-014-0458-4

Scientific article

English

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

ContributorsFinckh, Axel; Mc Carthy, Geraldine M; Madigan, Anne; Van Linthoudt, Daniel; Weber, Marcel; Neto, David; Rappoport, Georges; Blumhardt, Sandra; Kyburz, Diego; Guerne, Pierre-André

Published inArthritis research & therapy, vol. 16, no. 5, 458

Publication date2014

Abstract

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Mécanisme de l'inflammation articulaire (44)

Citation (ISO format)

FINCKH, Axel et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. In: Arthritis research & therapy, 2014, vol. 16, n° 5, p. 458. doi: 10.1186/s13075-014-0458-4

Article (Published version)

CC BY

Identifiers

PID : unige:45951
DOI : 10.1186/s13075-014-0458-4
PMID : 25315665

Journal ISSN1478-6354

610views

177downloads

Creation27/01/2015 15:26:00

First validation27/01/2015 15:26:00

Update time14/03/2023 22:45:57

Status update14/03/2023 22:45:56

Last indexation31/10/2024 17:18:08

Archive ouverte UNIGE

Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy.

Technical informations